Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Emerging Leaders
not ranked
Current Leaders
#2549 pts
All-Time Leaders
#3158 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2017. 26 trials as lead/chair. How it works →
Trials led — by scientific impact
CAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical Trial
Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical University
17
impact
CAR-T Targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR for Immunotherapy of Lung Cancer: Phase I Clinical Trial
Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical University
15
impact
Phase I Trial to Evaluate Safety and Preliminary Efficacy of CLDN6/GPC3/Mesothelin/AXL-CAR-NK in Patients With CLDN6/GPC3/Mesothelin/AXL-positive Advanced Solid Tumors
Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical University
13
impact
A Single-arm, Open-label, Phase I Study to Evaluate the Safety and Efficacy of CXCR5 Modified EGFR Chimeric Antigen Receptor Autologous T Cells in EGFR-positive Patients With Advanced Non-small Cell Lung Cancer
Early Ph 1RecruitingSecond Affiliated Hospital of Guangzhou Medical University
12
impact
Engineered TILs/CAR-TILs With PD1 Knockout and Anti-PD1/CTLA4-scFv Secreting or CARs Against Various Antigens to Treat Advanced Solid Tumors
Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical University
11
impact
A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors
Phase 3RecruitingSecond Affiliated Hospital of Guangzhou Medical University
11
impact
TCR-T Cells Targeting Cancer Cells for Immunotherapy of Lung Cancer and Other Solid Tumors: Phase I Clinical Trial
Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical University
10
impact
A Phase II/III Randomized Trial of Comparison of Survival Benefit of Administration of PD1/PDL1/CTLA4 Inhibitor or Their Combinations Via Hepatic Arterial Infusion Versus Vein for Immunotherapy of Advanced Liver Cancer
Phase 3RecruitingSecond Affiliated Hospital of Guangzhou Medical University
9
impact
Induced-T Cell Like NK Cellular Immunotherapy for Cancers That Are Lack of MHC-I Expression
Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical University
7
impact
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors
Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical University
7
impact
Triplex CTLA4/PD1/PDL1 Checkpoint Inhibitors Combination Therapy for Advanced Solid Tumors
Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical University
7
impact
Trametinib Combined With Everolimus and Lenvatinib in the Treatment of Recurrent/Refractory Advanced Solid Tumors: a Phase II Clinical Trial
Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical University
7
impact
Anti-cancer Neoantigen mRNA Vaccine to Treat Advanced Solid Tumors: Phase I Clinical Trial
Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical University
6
impact
Mesothelin/GPC3/GUCY2C Targeted CAR-T for Immunotherapy of Pancreatic Cancer: Phase I Clinical Trial
Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical University
6
impact
GPC3/Mesothelin Targeted CAR-γδT for Immunotherapy of Solid Cancer: Phase I Clinical Trial
Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical University
5
impact
Intra-tumor Injection of Drug-eluting Microspheres Loading With Chemodrug Plus Checkpoint Inhibitors and/or IL2 for Treatment of Advanced Solid Tumors
Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical University
4
impact
A Phase II/III Randomized Trial of Comparison of Survival Benefit of Administration of PD1/PDL1/CTLA4 Inhibitors or Their Combinations Via Neck Artery or Intratumor Versus Vein Infusion for Immunotherapy of HNC
Phase 3RecruitingSecond Affiliated Hospital of Guangzhou Medical University
3
impact
Intra-tumor Delivery of Double Checkpoint Inhibitors, Chemodrug, and/or Bevacizumab Therapy as First Line for Hepatocellular Carcinoma
Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical University
2
impact
Anti-cancer Neoantigen Polypeptide Vaccine to Treat Advanced Solid Tumors: Phase I Clinical Trial
Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical University
2
impact
Multicentre Perspective Non-interventional Study of Survival Benefits of iCAGES-guided Therapy in Contrast to Standard Therapy or IHC-guided Therapy for Advanced Cancers
N/ARecruitingSecond Affiliated Hospital of Guangzhou Medical University
1
impact
Intra-tumor Delivery of Double Checkpoint Inhibitors, Chemodrug, and/or Bevacizumab Therapy as First Line for Inoperable Lung Cancer
Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical University
1
impact
Phase II Study of Neoadjuvant CT-Guided Intra-tumor Double Checkpoint Blockades for Untreated Hepatocellular Carcinoma (HCC) Amenable for Surgical Resection
Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical University
1
impact
Phase II Study of Neoadjuvant CT-Guided Intra-tumor Double Checkpoint Blockades for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection
Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical University
0
impact
Anti-cancer DC Cell Vaccination to Treat Advanced Solid Tumors: Phase I Clinical Trial
Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical University
0
impact
Skin Drug Prepared From Stem Cell Derived Exome for Treatment of Diabetic Foot: a Phase II Clinical Trial
Phase 2Not Yet RecruitingSecond Affiliated Hospital of Guangzhou Medical University
0
impact
Interventional Software IRSW-MIM Guided Immunotherapy for Advanced Solid Tumors: a Phase II Clinical Trial.
Phase 3RecruitingSecond Affiliated Hospital of Guangzhou Medical University
0
impact